Compare Stryker Corporation (SYK) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Workiva Inc — how do they compare? Stryker Corporation trades at $277.33 (market cap $106.24B), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: Stryker Corporation is far larger — about 26.5× Workiva Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Workiva Inc for 21 Days on average.
| SYK | WK | |
|---|---|---|
Market Cap | $106.24B | $4.01B |
Volume | 2,982,001 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $388.35 | $93.31 |
52-Week Low | $269.75 | $44.31 |
Typical Hold Time | 21 Days | 21 Days |
Enterprise Value | $117.70B | $3.99B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Workiva (WK) trades at $73.25, up 2.4% with strong bullish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $885M in 2025 to $966M in 2026 and a shift to profitability with net income of $47M. Recent earnings beats and analyst optimism (16 buy ratings) support the positive momentum, though high valuation ratios (P/E 87.73) suggest premium pricing.
Outlook remains positive with consensus price target of $86 offering 17% upside potential. Key risks include elevated valuation metrics and competitive pressures in the regulatory technology space. The company's AI innovations and inclusion in analyst 'top picks' lists provide growth catalysts, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
